Giezen, T.J., Mantel-Teeuwisse, A.K. and Leufkens, H.G. (2009) Pharmacovigilance of Biopharmaceuticals: Challenges Remain. Drug Safety, 32, 811-817.
 Giezen, T.J., Mantel-Teeuwisse, A.K., Straus, S.M.J.M., Schellekens, H., Leufkens, H.G.M. and Egberts, A.C.G. (2008) Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union. JAMA, 300, 1887- 1896. https://doi.org/10.1001/jama.300.16.1887
 International Federation of Pharmaceutical Manufacturers & Associations (2016) Pharmacovigilance of Biotherapeutic Medicines: Identifying Global Case Studies Illustrating Successes and Challenges.
 O’Callaghan, J., Griffin, B.T., Morris, J.M. and Bermingham, M. (2018) Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland. BioDrugs, 32, 267-280.
 Sagi, S., Cohen, H.P. and Woollett, G.R. (2017) Pharmacovigilance of Biologics in a Multisource Environment. Journal of Managed Care & Specialty Pharmacy, 23, 1249- 1254. https://doi.org/10.18553/jmcp.2017.23.12.1249
 Vanderlaan, M., Maniatis, A., Olney, R., Rahmaoui, A., Yau, L., Quarmby, V., Azzolino, C., Woods, C. and Moawad, D. (2020) Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product. Clinical Pharmacology & Therapeutics, 107, 988-993. https://doi.org/10.1002/cpt.1694
 WHO Expert Committee on Biological Standardization (2013) Annexe 2. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). WHO Technical Report Series No. 977. World Health Organisation, Geneva.
 Claus, B.O., Lunddahl, B. and van Gelder, T. (2017) Pharmacovigilance, Traceability and Building Trust in Biosimilar Medicines. GaBI Journal, 6, 135-140.
 Annese, V., Solá, C., Breedveld, F., Ekman, N., Giezen, T., Gomollón, F., et al. (2016) Roundtable on Biosimilars with European Regulators and Medical Societies, Brussels, Belgium, 12 January 2016. Generics and Biosimilars Initiative Journal, 5, 74-83.
 Cassar, K., Zammit Dimech, D., Grech, L., Balzan, D., Cutajar, A. and Cassar, P.J. (2016) SAT0637-HPR Biosimilars: The Perception amongst Maltese Clinicians. Annals of the Rheumatic Diseases, 75, 1294.
 Reilly, M.S. and Gewanter, H.L. (2015) Prescribing Practices for Biosimilars: Questionnaire Survey Findings from Physicians in Argentina, Brazil, Colombia and Mexico. Generics and Biosimilars Initiative Journal, 4, 161-167.
 Karateev, D. and Belokoneva, N. (2019) Evaluation of Physicians’ Knowledge and Attitudes towards Biosimilars in Russia and Issues Associated with Their Prescribing. Biomolecules, 9, Article No. 57. https://doi.org/10.3390/biom9020057
 Klein, K., Hazell, L., Stolk, P. and Shakir, S. (2020) The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK. Drug Safety, 43, 255-263. https://doi.org/10.1007/s40264-019-00891-6
 Prashar, L. and Musoke, P. (2014) A Preliminary Study of Knowledge, Attitude and Practice of Adverse Drug Reaction Reporting in a Teaching Hospital in Lusaka, Zambia. Medical Journal of Zambia, 41, 155-161.
 GaBI Online—Generics and Biosimilars Initiative. Biosimilars in EU to Be Identified by Brand Names.
 Dolinar, R.O. and Reilly, M.S. (2014) Biosimilars Naming, Label Transparency and Authority of Choice-Survey Findings among European Physicians. Generics and Biosimilars Initiative Journal, 3, 58-62. https://doi.org/10.5639/gabij.2014.0302.018
 Murby, S.P. and Reilly, M.S. (2017) A Survey of Australian Prescribers’ Views on the Naming and Substitution of Biologicals. Generics and Biosimilars Initiative Journal, 6, 107-114. https://doi.org/10.5639/gabij.2017.0603.022
 Klein, K., Scholl, J.H., Vermeer, N.S., Broekmans, A.W., Van Puijenbroek, E.P., De Bruin, M.L., et al. (2016) Traceability of Biologics in the Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports. Drug Safety, 39, 185-192. https://doi.org/10.1007/s40264-015-0383-8
 Saavedra, M.A., Aimo, C. andrade, J.A., Alvarez, D., Sequeira, G. and Kerzberg, E. (2019) Survey on Transportation and Storage of Biological Therapies by Patients. European Journal of Rheumatology, 6, 94-97.
 Prashar, L., Jere, E. and Kalungia, C.A. (2019) Inadequate Knowledge and Practice of Pharmacovigilance Affecting Adverse Drug Reaction Reporting by Health Professionals in Private Healthcare Facilities in Lusaka, Zambia. Medical Journal of Zambia, 46, 314-320.
 Lopez-Gonzalez, E., Herdeiro, M.T. and Figueiras, A. (2009) Determinants of Under-Reporting of Adverse Drug Reactions: A Systematic Review. Drug Safety, 32, 19-31. https://doi.org/10.2165/00002018-200932010-00002
 Elnour, A.A., Ahmed, A.D., Yousif, M.A. and Shehab, A. (2009) Awareness and Reporting of Adverse Drug Reactions among Health Care Professionals in Sudan. Joint Commission Journal on Quality and Patient Safety, 35, 324-329.
 Terblanche, A., Meyer, J.C., Godman, B. and Summers, R.S. (2017) Knowledge, Attitudes and Perspective on Adverse Drug Reaction Reporting in a Public Sector Hospital in South Africa: Baseline Analysis. Hospital Practice (1995), 45, 238-245.
 Bogolubova, S., Padayachee, N. and Schellack, N. (2018) Knowledge, Attitudes and Practices of Nurses and Pharmacists towards Adverse Drug Reaction Reporting in the South African Private Hospital Sector. Health SA, 23, 1064.